Although intramedullary spinal cord tumors are predominantly primary tumors like ependymomas and astrocytomas, the intramedullary spinal cord metastatic tumors account for 4 to 9% of all such tumors. With the advent of magnetic resonance imaging (MRI) and improvement in the survival of cancer patients due to effective therapeutic options, the number of patients harboring intramedullary spinal cord metastasis (IMSCM) is increasing. Review of large series of IMSCM has revealed rarity of intramedullary metastasis to conus medullaris (IMCM). We present a short series of two cases of IMCM managed in our hospital and review of literature to describe how it is different from IMSCM at other regions of spinal cord. We also describe various management options available in the light of 25 cases of conus metastasis described in the literature till date.
INTRODUCTION
Though intramedullary spinal cord tumors are predominantly primary tumors like ependymomas and astrocytomas, the intramedullary spinal cord metastatic tumors account for 4 to 9% of all such tumors. 1 With the advent of MRI and improvement in the survival of cancer patients due to effective therapeutic options, the number of patients harboring IMSCM is increasing. This is evident from studies that show the actual numbers varying from 0.9 to 2.1% for autopsied cancer patients 2 to as much as 3.9% in other studies. 3 Kalyaci et al 4 reviewed
128 cases of IMSCM and found metastasis at all levels of the spinal cord (cervical 42%, thoracic 26%, and lumbar
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32%) but no metastasis was found in CM. Faillot et al 5 were the first to report a case of lung metastasis to the CM. 3 Since IMSCM is usually associated with brain metastasis and progressive systemic disease, the median survival of these patients is very short. 6 In view of short median survival, whether surgery or conservative treatment improves the quality of life is controversial and in view of rarity of the disease requires the careful study of the cases reported to form a consensus regarding the management. Although a common site for primary tumors, IMCM is very rare with only 25 cases reported in the literature till date. We present our two illustrative cases of IMCM metastasis and the review of literature. Our review of literature has found some basic differences in the metastatic disease at conus as compared with disease at other levels.
Illustrative Case 1
A 45-year-old lady who had undergone treatment 4 years earlier for stage T4N1M0 infiltrating duct cell carcinoma of breast gave history of pain and paresthesia in the perianal area and bilateral posterior thighs for last 1 month which was progressively worsening. She presented to our hospital with retention of urine for last 4 days. T1-weighted (T1W) MRI (Fig. 1A ) revealed a small eccentric hypointense lesion expanding the CM and enhancing strongly with contrast (Fig. 1B) . T2-weighted (T2W) MRI showed fusiform enlargement of conus (Fig. 1C) . Rest of the metastatic workup was normal. Patient underwent early D12-L1 laminectomy and tumor decompression. Tumor was bulging eccentrically from the surface and was moderately vascular. Histopathology was same as earlier reported from the breast specimen, i.e., infiltrating duct cell carcinoma (Fig. 1D) . Postoperatively, her pain improved markedly but paresthesias required small dose of gabapentin. Some bladder sensations returned after a week and she was discharged on catheter with instructions to clamp the catheter at regular intervals. Spine was irradiated locally and tamoxifen continued. At 3 months follow-up, she still required diapers and complained of pain on the right side of chest. Chest X-ray and isotope scan showed multiple metastasis to ribs and D2, D3 vertebral bodies. Ultrasonography abdomen showed multiple liver metastasis. Only supportive treatment was given and she died at 8 months.
Illustrative Case 2
A 48-year-old female, a known case of stage T4N2M0 infiltrating duct cell carcinoma who was undergoing postmastectomy chemotherapy (fourth cycle), presented with gradual onset weakness on bilateral lower limbs for last 10 days and incontinence of urine for last 2 days. She had moderate pain radiating to posterior thighs and numbness of perianal area. Bilateral lower limbs had a power of GII. The MRI spine revealed a mixed intensity lesion conus on T2W images and moderate contrast enhancement on T1W images (Figs 2A and B) . The MRI brain and rest of the metastatic workup was normal. She underwent D12-L1 laminectomy with tumor decompression, which was approached from midline myelotomy. Histopathology was same as previously reported from the breast specimen (Fig. 2C) . Postoperative, her bladder control returned after a week and power improved to GIV. At 1 month follow-up, she was walking with minimal support of a walking stick and bladder function completely recovered. She completed her chemotherapy and her spine was irradiated locally. Nine months later, she developed gradually worsening GIII left hemiparesis along with off and on headache. The MRI brain revealed 2 by 2.5 cm metastasis involving right motor cortex with significant surrounding edema and minimal midline shift. Decongestant and steroid therapy resulted in improvement of hemiparesis to GIV. Option of surgical excision of single metastatic lesion or whole brain radiation therapy (WBRT) was given. Family members decided in favor of WBRT; WBRT was given and tamoxifen continued. At home, her condition again deteriorated and she died after a month at 10 months. This time, her family members refused hospitalization.
DISCUSSION
Recently, effective therapeutic protocols for primary malignant diseases have increased the incidence of metastasis as a result of prolonging the life span of the patients. 7 The metastatic disease to central nervous system (CNS) is mainly localized to brain, IMSCM being comparatively uncommon. 8 Patients with IMSCM often have diseases at other levels of the CNS, as shown in one institution where 83% of patients had associated brain metastasis diagnosed before, after, or simultaneously hematogenous spread is more common especially in well-defined and circumscribed tumors. Leptomeningeal spread might be common in patients having multiple levels of spread within CNS. Hargraves et al, 21 proposed spread via a paravertebral plexus of veins (Batson's vein plexus) that become engorged during coughing and sneezing and promote intraspinal metastasis, as occurs in endometrial carcinoma. This process bypasses the portocaval and pulmonary circulation. Lung carcinoma is the most common IMSCM (64%), followed by breast (11%), melanoma (5%), renal cell cancer (4%), colorectal (3%), lymphoma (3%), and the remaining undiagnosed primaries. 2 The review of the reported cases of conus metastasis (Table 1) shows that lung carcinoma is again the most common type of metastasis to conus but constituting only 40.74% of all cases followed by breast carcinoma (33.33%), genitourinary tract (18.51%), and colon (7.4%). This is in contrast to ISCM at other levels where lung carcinoma constitutes approximately 64% of the cases. In case of conus metastasis, females outnumber males ( in females being breast carcinoma. Sensory symptoms, paraparesis, and bladder involvement are the commonest mode of presentation. Conus metastasis was the only manifestation of unknown primary in 15% of the cases. In contrast, only 3% presented as secondary manifestation of unknown primary at other levels of IMSCN. 1 This might be due to early progression of symptoms in case of conus lesions due to its distinct anatomy and physiology. In 18 patients where the interval between the onset of primary disease and diagnosis of conus metastasis was reported, the mean time to diagnosis was 32.33 months (1-96 months). Mean time to conus metastasis was 53.14 months for breast carcinoma and 9.75 months for carcinoma lungs. This might reflect aggressiveness of the primary disease as well as more effective therapy for Ca breast. Both the patients of prostatic carcinoma had far advanced disease (Gleason G 4+3) at presentation. At the time of presentation, brain metastasis which is the commonest site of diseases was seen in 22% of the 20 patients where it was reported and 13% developed brain metastasis during or after the treatment of conus metastasis. This is contrary to the 83% incidence of brain metastasis reported for IMSCM. 9 Eight patients underwent only surgery, eight underwent surgery plus radiotherapy and/or chemotherapy, and four patients underwent only radiotherapy and/ or chemotherapy. Three patients either refused treatment or no treatment was offered. Mean survival was 8.2 months, with longest survivor alive at 24 months. Patients who underwent surgery plus radiotherapy and/or chemotherapy had a survival of 9.4 months, only surgery had a survival of 7.5 months, only radiotherapy and/or chemotherapy a survival of 8.5 months, and patients who received no treatment had a survival of 2.5 months only. Mean survival in breast carcinoma patients was 10.6 months, whereas survival in lung carcinoma was 5.7 months only. This is consistent with prior reports demonstrating poor survival after diagnosis of IMSCM. 22 Kalayci et al 4 reviewed the literature and conducted a meta-analysis of 284 patients with IMSCM. In the 94 patients for whom survival data were available, the median overall survival was 7.3 months and tended to be longer in patients treated surgically (9.4 months) compared with that of patients who did not undergo surgery (5 months). Lee et al 9 reported a median overall survival of 3.9 months in 12 patients with IMSCM treated nonsurgically at a single institution. Other investigators report durations of survival after diagnosis of ISCM ranging from 3 weeks to 27 months. 1 The mean survival in our review
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of conus metastasis appears consistent with prior reports of survival in IMSCM and suggests a marginal survival benefit from surgery.
Clinical outcome was reported in 16 cases (Table 1 ) out of which 81.25% of patients had some clinical improvement, whereas 18.75% had no reported improvement. Out of these 16 cases, 15 patients had undergone surgery. Out of this surgical group, 80% had some clinical improvement though it did not translate into substantial overall survival. From the above figures, it is clear that patients with some form of treatment have longer survival than patients who receive no treatment at all. Also surgical treatment may be reasonable to preserve clinical status in symptomatic patients with marginal survival benefits. Also lung carcinoma patients have the worst prognosis. This might reflect aggressiveness of the primary disease as well as more effective therapy for Ca breast.
In our series, both the patients (Table 2) were females with infiltrating duct cell carcinoma of breast. Mean age at presentation was 46.5 years and mean age to conus metastasis from diagnosis of primary disease was 26.5 months. At the time of diagnosis, none of the patients had brain metastasis while one patient developed metastasis at 9 months. Both our patients underwent early surgery followed by radiation and continuation of chemotherapy. Both patients showed good early clinical response to treatment with a mean survival of 9 months, which is consistent with the results reported in the review of literature.
CONCLUSION
We conclude that conus metastasis should be considered in the differential diagnosis of patients presenting with bladder involvement, especially in those who have an established diagnosis of primary neoplastic disease. Breast carcinoma metastasis to conus being commonest in females has longer survival as compared with conus metastasis from lung carcinoma, which is more common in males. Despite different modalities of treatment, the overall prognosis remains poor, with best results seen with surgery along with radiation and chemotherapy. Poor prognosis seems to be related to the presence of advanced metastatic disease to conus itself at the time of presentation. 
